AKT1 and Proteus syndrome: Hence, to maintain pathway inhibition and minimize toxicities shown to occur with AKT inhibitors when the pathway is strongly inhibited23, we anticipate that a tissue level of no more than 125 nM of ARQ 092 should be sufficient to accomplish this objective in patients with Proteus syndrome.